News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
261,799 Results
Type
Article (13950)
Company Profile (304)
Press Release (247545)
Section
Business (79358)
Career Advice (151)
Deals (13191)
Drug Delivery (34)
Drug Development (50332)
Employer Resources (31)
FDA (5682)
Job Trends (5116)
News (144139)
Policy (10018)
Tag
Academia (901)
Alliances (21529)
Alzheimer's disease (760)
Approvals (5665)
Artificial intelligence (69)
Bankruptcy (97)
Best Places to Work (4522)
Biotechnology (249)
Breast cancer (110)
Cancer (894)
Cardiovascular disease (71)
Career advice (132)
CAR-T (73)
Cell therapy (217)
Clinical research (40151)
Collaboration (311)
Compensation (129)
COVID-19 (1007)
C-suite (79)
Cystic fibrosis (67)
Data (986)
Diabetes (87)
Diagnostics (1207)
Drug discovery (57)
Earnings (29007)
Events (47199)
Executive appointments (249)
FDA (6055)
Funding (310)
Gene editing (63)
Gene therapy (163)
GLP-1 (311)
Government (1065)
Healthcare (6545)
Infectious disease (1045)
Inflammatory bowel disease (98)
IPO (7200)
Job creations (859)
Job search strategy (127)
Layoffs (188)
Legal (1375)
Lung cancer (131)
Lymphoma (62)
Manufacturing (87)
Medical device (2560)
Medtech (2561)
Mergers & acquisitions (6131)
Metabolic disorders (262)
Neuroscience (1006)
NextGen Class of 2024 (2004)
Non-profit (847)
Northern California (1096)
Obesity (142)
Opinion (91)
Parkinson's disease (78)
Patents (63)
People (25109)
Phase I (14157)
Phase II (18669)
Phase III (11821)
Pipeline (367)
Postmarket research (851)
Preclinical (5971)
Radiopharmaceuticals (205)
Rare diseases (204)
Real estate (1410)
Regulatory (8289)
Research institute (931)
Southern California (983)
Startups (1964)
United States (8717)
Vaccines (165)
Weight loss (84)
Date
Last 7 days (145)
Last 30 days (1319)
Last 365 days (20562)
2024 (20528)
2023 (22413)
2022 (26822)
2021 (27805)
2020 (23357)
2019 (16224)
2018 (11738)
2017 (13745)
2016 (11839)
2015 (14349)
2014 (10392)
2013 (7484)
2012 (7532)
2011 (7614)
2010 (7428)
Location
Africa (146)
Asia (16929)
Australia (2856)
California (2488)
Canada (817)
China (206)
Colorado (93)
Connecticut (104)
Europe (36452)
Florida (273)
Georgia (71)
Illinois (154)
Indiana (61)
Maryland (336)
Massachusetts (1961)
Michigan (58)
Minnesota (101)
New Jersey (635)
New York (692)
North Carolina (420)
Northern California (1096)
Ohio (82)
Pennsylvania (478)
South America (207)
Southern California (983)
Texas (282)
Washington State (249)
261,799 Results for "janux therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Janux Therapeutics Announces Proposed Public Offering
December 3, 2024
·
4 min read
Business
Janux Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux) today reported financial results for the first quarter ended March 31, 2024 and provided a business update.
May 7, 2024
·
7 min read
Press Releases
Janux Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights
November 7, 2024
·
7 min read
Press Releases
Janux Therapeutics Announces Pricing of $350.0 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants
December 5, 2024
·
5 min read
Business
Janux Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux) today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a business update.
March 8, 2024
·
9 min read
Biotech Beach
Janux’s Stock Skyrockets 172% on Positive Results for Two Candidates in Phase I Trials
Janux Therapeutics on Monday announced positive updated clinical data for both of its clinical programs in prostate cancer advanced or metastatic solid tumors.
February 27, 2024
·
2 min read
·
Tyler Patchen
Press Releases
Janux Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Pre-Funded Warrants Including Full Exercise of Underwriters’ Option to Purchase Additional Shares for Total Gross Proceeds of $402.5 Million
December 9, 2024
·
4 min read
Press Releases
Janux Therapeutics to Host Virtual Event Discussing Updated Clinical Data in Phase 1a Dose Escalation for JANX007 in mCRPC and Doses Selected for Phase 1b Expansion Studies
November 25, 2024
·
4 min read
Biotech Beach
Janux Therapeutics Announces Proposed Public Offering of Common Stock
Janux Therapeutics, Inc., a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager and Tumor Activated Immunomodulator platforms, announced that it has commenced an underwritten public offering of $175.0 million of shares of its common stock.
February 27, 2024
·
4 min read
Business
Janux Therapeutics Promotes Co-Founder Tommy DiRaimondo, Ph.D. to Chief Scientific Officer
Janux Therapeutics, Inc. today announced the promotion of Dr. Tommy DiRaimondo to Chief Scientific Officer.
January 8, 2024
·
5 min read
1 of 26,180
Next
